Effect of perioperative flurbiprofen axetil on long‐term survival of patients with esophageal carcinoma who underwent thoracoscopic esophagectomy: A retrospective study

Yanhu Xie, Di Wang, Chen Gao, Ji‐cheng Hu, Min Zhang, Wei Gao, Shuhua Shu, Xiaoqing ChaiJournal of Surgical Oncology 2021 · DOI

TL;DR

This retrospective study investigated the impact of perioperative flurbiprofen axetil (a non-steroidal anti-inflammatory drug, NSAID) on long-term survival in patients undergoing thoracoscopic esophagectomy for esophageal cancer. The findings suggest that using flurbiprofen axetil during the perioperative period is associated with improved recurrence-free survival (RFS) and overall survival (OS), independent of the dosage regimen.

What Problem Does This Paper Address?

Esophageal carcinoma is a particularly aggressive cancer with a high rate of recurrence and poor overall survival, even after surgical resection. While esophagectomy is the primary treatment for resectable cases, locoregional recurrence and distant metastases remain significant challenges, occurring in approximately 50% of patients within 2-3 years post-surgery. The perioperative period is a critical window where factors like immune suppression can accelerate micrometastatic disease. Existing research has hinted that certain perioperative interventions, including NSAIDs, might positively influence outcomes by mitigating immunosuppression and reducing pain, thereby potentially improving patient survival. However, the specific effect of flurbiprofen axetil, a commonly used NSAID for pain management, on long-term survival in esophageal cancer patients undergoing thoracoscopic esophagectomy remained unclear. This study aimed to fill that knowledge gap.

Methods

This was a retrospective study conducted at the Anhui Provincial Hospital, involving patients who underwent thoracoscopic esophagectomy for esophageal carcinoma between December 2009 and May 2015. Patients were categorized into three groups:

  • Non-NSAIDs group: Did not receive flurbiprofen axetil.
  • Single-dose NSAIDs group: Received a single intravenous dose of flurbiprofen axetil (100 mg) before anesthesia.
  • Multiple-dose NSAIDs group: Received a single dose before anesthesia, followed by intravenous infusions twice daily for two days post-surgery.

The primary endpoints were recurrence-free survival (RFS) and overall survival (OS). RFS was defined as the time from surgery until the first recurrence or death from cancer. OS was defined as the time from surgery until death from any cause. Statistical analyses included univariable and multivariable Cox proportional hazards models to identify prognostic factors and Kaplan-Meier analyses to estimate survival probabilities.

Datasets

The study utilized data from 847 eligible patients who underwent thoracoscopic esophagectomy at the Anhui Provincial Hospital. Patient data was retrieved from the hospital's medical record database. No new datasets were introduced.

Key Insights and Ideas

  • NSAIDs as a potential survival enhancer: The study strongly suggests that perioperative flurbiprofen axetil administration is linked to better long-term outcomes in esophageal cancer patients. This aligns with the broader hypothesis that modulating the perioperative inflammatory and immune response can impact cancer progression.
  • Dose-independent benefit: Interestingly, the study found no significant difference in RFS or OS between patients receiving a single dose versus multiple doses of flurbiprofen axetil. This implies that the benefit might be derived from the initial perioperative exposure rather than sustained use, suggesting a potential role in modulating early post-surgical events that influence recurrence.
  • Immune modulation hypothesis: While not directly measured, the authors speculate that flurbiprofen axetil might modify immune-checkpoint expression (like PD-1/PD-L1), which is often dysregulated in cancer and can contribute to immune evasion and recurrence. This offers a plausible biological mechanism for the observed survival benefits.
  • Prognostic importance of tumor stage and lymph nodes: Consistent with existing literature, advanced tumor stage and lymph node invasion were identified as significant independent risk factors for poorer RFS and OS in patients who did not receive flurbiprofen axetil. This highlights the continued importance of these traditional prognostic markers.

Key Results

  • Improved Survival with Flurbiprofen: Univariable and multivariable analyses revealed that intraoperative flurbiprofen use was significantly associated with a reduced risk of recurrence (HR: 0.56, 95% CI: 0.42-0.76, p = .001) and prolonged overall survival (HR: 0.49, 95% CI: 0.38-0.63, p = .001).
  • No Dose-Response: There was no statistically significant difference in RFS or OS between the single-dose and multiple-dose flurbiprofen axetil groups.
  • Risk Factors: In patients not receiving flurbiprofen, increasing tumor stage and lymph node invasion were significant predictors of worse outcomes.

Limitations and Future Work

The authors acknowledge several limitations inherent to this retrospective, observational study:

  • Potential Biases: Uncontrolled and unrecognized biases, such as selection bias, diagnostic bias, and follow-up bias, may have influenced the results.
  • Generalizability: The single-center design may limit the generalizability of the findings to other populations or healthcare settings.
  • Confounding Factors: Data on neoadjuvant chemotherapy, adjuvant radiation, or other adjuvant therapies were unavailable, which could have impacted the study endpoints.
  • Dosage Regimen: The study compared a single dose versus a specific multiple-dose regimen, and individualized dosage regimens based on patient and tumor characteristics were not explored.

Future work should focus on prospective, randomized controlled trials to definitively ascertain the efficacy of perioperative flurbiprofen axetil. These trials could also explore its potential role in immune-checkpoint blockade therapy and establish it as a standard of care for patients undergoing thoracoscopic esophagectomy. Further research could also investigate the precise immunological mechanisms through which flurbiprofen axetil exerts its beneficial effects.

Summary updated

Abstract

Perioperative flurbiprofen axetil therapy may be associated with prolonged RFS and OS in patients with esophageal carcinoma undergoing thoracoscopic esophagectomy.
BibTeX
@article{xie2021effect,
  author = {Yanhu Xie and Di Wang and Chen Gao and Ji‐cheng Hu and Min Zhang and Wei Gao and Shuhua Shu and Xiaoqing Chai},
  title = {{Effect of perioperative flurbiprofen axetil on long‐term survival of patients with esophageal carcinoma who underwent thoracoscopic esophagectomy: A retrospective study}},
  journal = {Journal of Surgical Oncology},
  year = {2021},
  doi = {10.1002/jso.26553},
}
Figure